1. O-007Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (20th June 2018) Authors: Rossini, D; Cremolini, C; Conca, E; Del Re, M; Busico, A; Pietrantonio, F; Bergamo, F; Danesi, R; Cardellino, G; Tamburini, E; Dell'Aquila, E; Strippoli, A; Masi, G; Tonini, G; Negri, F; Corsi, D; Pella, N; Intini, R; Falcone, A; Santini, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗